Sadowsky, C. H., Farlow, M. R., Meng, X., Olin, J. T.

Objectives: To compare the safety and tolerability of switching patients with mild-to-moderate Alzheimer’s disease from donepezil to either rivastigmine capsule or transdermal patch.; Methods: Three studies investigated the switch from donepezil to rivastigmine; study US13 was a 26-week, single-arm, immediate-switch study; US18 was a 26-week, sequential cohort study (both studies evaluated rivastigmine capsules 3-12 mg/day); […]

Husebo, B. S., Ballard, C., Sandvik, R., Nilsen, O. B., Aarsland, D.

Objective: To determine whether a systematic approach to the treatment of pain can reduce agitation in people with moderate to severe dementia living in nursing homes.; Design: Cluster randomised controlled trial.; Setting: 60 clusters (single independent nursing home units) in 18 nursing homes within five municipalities of western Norway.; Participants: 352 residents with moderate to […]

Husebo, B. S., Ballard, C., Fritze, F., Sandvik, R. K., Aarsland, D.

Background: Depression is common in nursing home (NH) patients with dementia, and often clustered with anxiety and other mood symptoms. An association between pain and depressive symptoms has been reported, but the impact of pain management on depression and other mood symptoms has not been investigated. Objective: Secondary analyses of a cluster randomized clinical trial […]

Grossberg, G., Cummings, J., Frolich, L., Bellelli, G., Molinuevo, J. L., Krahnke, T., Strohmaier, C.

Background: Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer’s disease (AD).; Methods: Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer’s disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24 h rivastigmine patch in patients with AD demonstrating functional and cognitive decline with […]

Farlow, Martin R., Grossberg, George T., Sadowsky, Carl H., Meng, Xiangyi, Somogyi, Monique

Aims: The 24-week, prospective, randomized, double-blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer’s disease (AD).; Methods: Patients had probable AD and Mini-Mental State Examination scores ≥3-≤12. Primary outcome measures were as follows: Severe Impairment Battery (SIB) and AD Cooperative Study-Activities of […]

Choi, Seong Hye, Park, Kyung Won, Na, Duk L., Han, Hyun Jeong, Kim, Eun-Joo, Shim, Yong S., Lee, Jae-Hong, The EXPECT Study Group,

Objective: To compare the tolerability and efficacy of combination therapy of memantine plus rivastigmine patch with rivastigmine patch monotherapy in patients with mild to moderate Alzheimer’s disease (AD).; Research Design and Methods: In this multicenter, randomized, open-label study, patients entered an 8-week run-in period (a 5 cm 2 rivastigmine patch for 4 weeks, then a […]

Aguiar, Paula, Monteiro, Larissa, Feres, Ana, Gomes, Irenio, Melo, Ailton

Objective: To determine the effects of rivastigmine patch associated with physical exercise versus rivastigmine patch alone in quality of life (QOL), cognition, activities of daily living (ADL) and functional mobility in Alzheimer’s disease (AD)subjects. Methods: A randomized, controlled, single-blinded trial was conducted in 40 patients with mild to moderate stages of AD. All patients were […]